While experts agree that none of these options are clearly superior in terms of efficacy and tolerability [10], a recent pragmatic randomized clinical trial comparing these three therapies in patients with PD and levodopa-related motor complications found no functional advantage of dopamine agonists over the combined group of MAO-B or COMT inhibitors, as evaluated with the mobility subscale of the 39-item Parkinson’s disease questionnaire (PDQ-39). This evidence concerns the gene MAOB and Parkinson disease.